Document is current
Any future updates will be listed below
-
Authors
Dimitrion, Peter
Hamzavi, Iltefat
Yin, Congcong https://orcid.org/0000-0003-0865-2823
Toor, Jugmohit
Subedi, Kalpana
Khalasawi, Namir
Miller, Angela
Huggins, Richard
Adrianto, Indra https://orcid.org/0000-0002-9973-3057
Veenstra, Jesse
Vellaichamy, Gautham
Hans, Aakash
Daveluy, Steven
Athar, Mohammad
Liao, Wilson
Lim, Henry
Ozog, David
Zhou, Li
Mi, Qing-Sheng https://orcid.org/0000-0002-1411-6827
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR078688, R21AR079089, R21AR079089, R01AR078688)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases
- License Information
-
More Information
Article History
Received: 25 April 2023
Accepted: 3 May 2023
First Online: 29 May 2023
Competing interests
: IH has served as an investigator (grant to institution) for Pfizer Inc, Bayer, Lenicura, Incyte, Estee Lauder, L’Oreal, Unigen, Avita, Arcutis Biotherapeutics, and Ferndale Laboratories, Inc.; as an Advisory Board member for AbbVie; and as a consultant to Galderma Laboratories, LP, Incyte, Pfizer, UCB, Boehringer Ingelheim, Beiersdorf, and Clarify Medical. RH is a principal investigator for Pfizer, Incyte, Arcutis and the Immune Tolerance Network. WL has received research grant funding from AbbVie, Amgen, Janssen, Leo, Novartis, Pfizer, Regeneron, and TRex Bio. HL is an investigator for Incyte, L’Oreal, Pfizer, and PCORI; has served as a consultant for Pierre Fabre, ISDIN, Ferndale, La Roche-Posay, Cantabria, and Beiersdorf; and has participated as a speaker in general educational sessions for La Roche-Posay and Cantabria Labs. All other authors have no conflicts of interest to report.
: These procedures and protocols were approved by the Henry Ford Health Institutional Review Board (IRB# 12826).
